The thymidine phosphorylase imaging agent 123I-IIMU predicts the efficacy of capecitabine

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1276-1281

  Kobashi, Nobuya ^a   Matsumoto, Hiroki ^a   Zhao, Songji ^b   Meike, Shunsuke ^a   Okumura, Yuki ^a   Abe, Tsutomu ^a   Akizawa, Hiromichi ^c   Ohkura, Kazue ^d   Nishijima, Ken Ichi ^b   Tamaki, Nagara ^b   Kuge, Yuji ^b,e  

^a Nihon Medi Physics   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^d HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Companion diagnostics; Doxifluridine; Single photon emission computed tomography; Uracil derivative

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; IODINE 123 5 IODO 6 [(2 IMINOIMIDAIMINOIMIDAZOLIDINYL)]; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; 5' NUCLEOTIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER CELL LINE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; WST ASSAY; ANIMAL; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; DIAGNOSTIC IMAGING; DRUG MONITORING; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MOLECULAR IMAGING; NUDE MOUSE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TREATMENT OUTCOME; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ANIMALS; CAPECITABINE; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; TREATMENT OUTCOME;

EID: 84982822179     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.165811     Document Type: Article

References (37)

1. 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med. 2008;49:899-906.
2. 99mTc-etarfolatide). Ann Oncol. 2014;25:852-858.
3. 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J Nucl Med. 2014;55:701-704.
4. Laing RE, Walter MA, Campbell DO, et al. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci USA. 2009;106:2847-2852.
5. 18F-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-tasman radiation oncology group study 98.02. J Clin Oncol. 2006;24:2098-2104.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
7. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673.
8. Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer. 2006;13:49-57.
9. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of cape-citabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.
10. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyr-imidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337-1345.
11. Takebayashi Y, Yamada K, Miyadera K, et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer. 1996;32A:1227-1232.
12. Bonotto M, Bozza C, Di Loreto C, et al. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase? Clin Breast Cancer. 2013;13:167-172.
13. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Che-mother Pharmacol. 2000;45:291-297.
14. Lee SJ, Choi YL, Park YH, et al. Thymidylate synthase and thymidine phos-phorylase as predictive markers of capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2011;68:743-751.
15. Koizumi W, Okayasu I, Hyodo I, et al. Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs. 2008;19:819-824.
16. Petrioli R, Bargagli G, Lazzi S, et al. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. Anticancer Drugs. 2010;21:313-319.
17. Naruke A, Azuma M, Takeuchi A, et al. Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer. Gastric Cancer. 2015;18:262-270.
18. Vallböhmer D, Kuramochi H, Shimizu D, et al. Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol. 2006;28:527-533.
19. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6:158-166.
20. Griffiths L, Dachs GU, Bicknell R, et al. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 1997;57:570-572.
21. Puglisi F, Andreetta C, Valent F, et al. Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells. Anticancer Drugs. 2007;18:883-888.
22. Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 59-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999;83:127-134.
23. Zhang SH, Zhang H, He HW, et al. Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma. Cancer Chemother Pharmacol. 2013;72:777-788.
24. Takahashi M, Seki K, Nishijima K, et al. Synthesis of a radioiodinated thymidine phosphorylase inhibitor and its preliminary evaluation as a potential SPECT tracer for angiogenic enzyme expression. J Labelled Comp Radiopharm. 2008;51:384-387.
25. Akizawa H, Zhao S, Takahashi M, et al. In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging. Nucl Med Biol. 2010;37:427-432.
26. Li H, Zhao S, Jin Y, et al. Radiolabeled uracil derivative as a novel SPECT probe for thymidine phosphorylase: suppressed accumulation into tumor cells by target gene knockdown. Nucl Med Commun. 2011;32:1211-1215.
27. Zhao S, Li H, Nishijima K, et al. Relationship between biodistribution of a novel thymidine phosphorylase (TP) imaging probe and TP expression levels in normal mice. Ann Nucl Med. 2015;29:582-587.
28. Thanasai J, Limpaiboon T, Jearanaikoon P, et al. Effects of thymidine phosphor-ylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarci-noma. World J Gastroenterol. 2010;16:1631-1638.
29. Ishikawa T, Fukase Y, Yamamoto T, et al. Antitumor activities of a novel fluo-ropyrimidine, N4-pentyloxycarbonyl-59-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull. 1998;21:713-717.
30. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
31. Yasuno H, Kurasawa M, Yanagisawa M, et al. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes. Oncol Rep. 2013;29:451-458.
32. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xeno-grafts. Cancer Res. 1998;58:685-690.
33. Yang Q, Barbareschi M, Mori I, et al. Prognostic value of thymidine phosphor-ylase expression in breast carcinoma. Int J Cancer. 2002;97:512-517.
34. Ogawa M, Watanabe M, Mitsuyama Y, et al. Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer. Oncol Lett. 2014;8:2463-2468.
35. Ishii R, Takiguchi N, Oda K, et al. Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol. 2001;19:717-722.
36. Kikuyama S, Inada T, Shimizu K, et al. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res. 2001;21:2149-2153.
37. Yamamoto Y, Toi M, Tominaga T. Prediction of the effect of 59-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Rep. 1996;3:863-865.